Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070042 · ClinicalTrials.gov registry record · NA
Oxybutynin and Omega-3 for OAB (Overactive Bladder)
A NA study, sponsored by TriHealth.
- Terminated
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02070042 is a NA study that was terminated before completion, run by TriHealth. The registered enrollment target is 31 participants.
The verdict
NCT02070042, a NA study, was terminated before completion, sponsored by TriHealth.
- TERMINATED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard first-line treatment for overactive bladder syndrome, will improve symptoms and quality of life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse effects of oxybutynin. Hypothesis * Primary: Omega-3 will enhance the beneficial role of oxybutynin in the treatment of overactive bladder (OAB) * Secondary: Omega-3 will reduce the side effects of dry eyes and constipation associated with oxybutynin
Interventions
- DRUG Placebo
- DRUG Omega 3 Fatty Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02070042
The ClinicalTrials.gov registry entry for NCT02070042 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02070042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02070042 about?
NCT02070042 is a clinical study titled "Oxybutynin and Omega-3 for OAB (Overactive Bladder)". We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard first-line treatment for overactive bladder syndrome, will improve symptoms and quality of life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse effects of oxybutynin. Hypothes...
What is the current status of trial NCT02070042?
This trial is currently terminated. It is a NA study. The enrollment target is 31 participants. The study started on 2014-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02070042?
The interventions under investigation include: Placebo (DRUG), Omega 3 Fatty Acid (DRUG).
Who is sponsoring clinical trial NCT02070042?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.